Rapt Therapeutics Stock Today
| RAPT Stock | USD 7.80 0.10 1.27% |
Performance0 of 100
| Odds Of DistressLess than 8
|
RAPT Therapeutics is selling for under 7.80 as of the 26th of April 2024; that is -1.27 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 7.52. RAPT Therapeutics has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for RAPT Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of March 2024 and ending today, the 26th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of October 2019 | Category Healthcare | Classification Health Care |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. The company has 34.8 M outstanding shares of which 3.18 M shares are at this time shorted by private and institutional investors with about 3.47 trading days to cover. More on RAPT Therapeutics
Moving against RAPT Stock
| 0.85 | VKTX | Viking Therapeutics Buyout Trend | PairCorr |
| 0.76 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.7 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.6 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.58 | BMY | Bristol Myers Squibb | PairCorr |
| 0.58 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.52 | HEPA | Hepion Pharmaceuticals Financial Report 10th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
RAPT Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. RAPT Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding RAPT Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Brian MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering RAPT Therapeutics report their recommendations after researching RAPT Therapeutics' financial statements, talking to executives and customers, or listening in on RAPT Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering RAPT Therapeutics. The RAPT consensus assessment is calculated by taking the average forecast from all of the analysts covering RAPT Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to RAPT Therapeutics' liquidity, profitability, solvency, and operating efficiency, RAPT Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of RAPT Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RAPT Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to RAPT Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand RAPT Therapeutics' financial leverage. It provides some insight into what part of RAPT Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RAPT Therapeutics (RAPT) is traded on NASDAQ Exchange in USA. It is located in 561 Eccles Avenue, South San Francisco, CA, United States, 94080 and employs 131 people. RAPT Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 274.92 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate RAPT Therapeutics's market, we take the total number of its shares issued and multiply it by RAPT Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. RAPT Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.8 M outstanding shares of which 3.18 M shares are at this time shorted by private and institutional investors with about 3.47 trading days to cover.
RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99.
Check RAPT Therapeutics Probability Of Bankruptcy
Ownership AllocationRAPT Therapeutics has a total of 34.8 Million outstanding shares. The majority of RAPT Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in RAPT Therapeutics to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in RAPT Therapeutics. Please pay attention to any change in the institutional holdings of RAPT Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check RAPT Ownership Details
RAPT Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of RAPT Therapeutics jumping above the current price in 90 days from now is about 77.23%. The RAPT Therapeutics probability density function shows the probability of RAPT Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.4712 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, RAPT Therapeutics will likely underperform. Additionally, rAPT Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of RAPT Therapeutics to move above the current price in 90 days from now is about 77.23 (This RAPT Therapeutics probability density function shows the probability of RAPT Stock to fall within a particular range of prices over 90 days) .
RAPT Stock Institutional Holders
Institutional Holdings refers to the ownership stake in RAPT Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of RAPT Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing RAPT Therapeutics' value.| Instituion | Recorded On | Shares | |
| Braidwell Lp | 2023-09-30 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1 M | |
| Samlyn Capital, Llc | 2023-12-31 | 711.5 K | |
| Geode Capital Management, Llc | 2023-12-31 | 669.3 K | |
| Euclidean Capital Llc | 2023-12-31 | 657.9 K | |
| Alphabet Inc | 2023-12-31 | 540.3 K | |
| Timessquare Capital Management, Llc | 2023-12-31 | 504.3 K | |
| Cormorant Asset Management, Llc | 2023-12-31 | 496.8 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 488.3 K | |
| Fmr Inc | 2023-12-31 | 3.8 M | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 3.4 M |
RAPT Therapeutics Historical Income Statement
RAPT Therapeutics Income Statement is one of the three primary financial statements used for reporting RAPT's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of RAPT Therapeutics revenue and expense. RAPT Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, RAPT Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 1.3 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 71.6 M in 2024. View More FundamentalsRAPT Stock Against Markets
Picking the right benchmark for RAPT Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in RAPT Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for RAPT Therapeutics is critical whether you are bullish or bearish towards RAPT Therapeutics at a given time. Please also check how RAPT Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in RAPT Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
RAPT Therapeutics Corporate Management
Elected by the shareholders, the RAPT Therapeutics' board of directors comprises two types of representatives: RAPT Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RAPT. The board's role is to monitor RAPT Therapeutics' management team and ensure that shareholders' interests are well served. RAPT Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RAPT Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwen Carscadden | Chief Officer | Profile | |
| Rodney Young | Principal CFO | Profile | |
| David Wustrow | Senior Development | Profile | |
| William Ho | Chief Officer | Profile | |
| Jennifer Nicholson | Senior Assurance | Profile | |
| Michael Listgarten | General Counsel | Profile | |
| William MD | Chief Officer | Profile |
How to buy RAPT Stock?
Before investing in RAPT Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in RAPT Therapeutics. To buy RAPT Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of RAPT Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase RAPT Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located RAPT Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased RAPT Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as RAPT Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.
Already Invested in RAPT Therapeutics?
The danger of trading RAPT Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of RAPT Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than RAPT Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile RAPT Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether RAPT Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if RAPT Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Rapt Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Rapt Therapeutics Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for RAPT Stock analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is RAPT Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of RAPT Therapeutics. If investors know RAPT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about RAPT Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.36) | Return On Equity (0.60) |
The market value of RAPT Therapeutics is measured differently than its book value, which is the value of RAPT that is recorded on the company's balance sheet. Investors also form their own opinion of RAPT Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is RAPT Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because RAPT Therapeutics' market value can be influenced by many factors that don't directly affect RAPT Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between RAPT Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if RAPT Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, RAPT Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.